Chronic Kidney Disease Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Chronic Kidney Disease stocks.

Chronic Kidney Disease Stocks Recent News

Date Stock Title
May 20 SNY Sanofi Receives Another Approval for Blockbuster Drug Dupixent
May 20 SNY FDA Approves Regeneron and Sanofi's Dupixent (dupilumab) For Eosinophilic Esophagitis (EoE) Ahead of Schedule
May 20 SNY Sanofi wins FDA label expansion for Dupixent for new inflammatory condition
May 20 SNY FDA Approves Dupixent® (dupilumab) as First Treatment for Adults and Children Aged 12 and Older with Eosinophilic Esophagitis
May 20 SNY Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis
May 20 SNY UPDATE 2-Sanofi's Dupixent wins U.S. approval for bigger use
May 20 KDNY Chinook Therapeutics Presents Data from Atrasentan Phase 2 AFFINITY IgA Nephropathy (IgAN) Patient Cohort and Evotec Collaboration at the 59th European Renal Association (ERA) Congress 2022
May 20 AZN Pharma Stock Roundup: FDA Nod to PFE COVID Jab for Age 5-11 & LLY's Tirzepatide
May 20 SNY The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20 KDNY The Daily Biotech Pulse: CDC Recommends COVID-19 Boosters For Kids 5-11, Foghorn's Blood Cancer Trial On Clinical Hold, Bayer Intends To Bow Out From CAR-T Therapy Pact With Atara
May 20 SNY This Safe Stock Is Dirt Cheap -- and It's Beating the Market
May 20 SNY Sanofi gets EMA panel nod for enzyme replacement therapy Xenpozyme
May 19 AZN Antibiotic resistance efforts get a boost as CARB-X gets $370M
May 19 AZN UPDATE 1-EU health regulator backs using AstraZeneca COVID shot as booster
May 19 AZN AstraZeneca COVID-19 vaccine wins EU nod as a booster shot
May 19 TCDA Read Why Did Tricida Stop VALOR-CKD Renal Outcomes Trial Early
May 19 TCDA Tricida stops kidney disease study of veverimer due to administrative reasons
May 19 AZN Merck (MRK) Outperforms Industry This Year So Far: Here's Why
May 19 TCDA Tricida Announces Administrative Stop of the VALOR-CKD Trial
May 19 KDNY Chinook Therapeutics Presents Updated Data from BION-1301 Phase 1/2 Trial in Patients with IgA Nephropathy (IgAN) and from Atrasentan Preclinical Mechanism of Action Studies at the 59th European Renal Association (ERA) Congress 2022

Chronic kidney disease (CKD) is a type of kidney disease in which there is gradual loss of kidney function over a period of months or years. Early on there are typically no symptoms. Later, leg swelling, feeling tired, vomiting, loss of appetite, or confusion may develop. Complications may include heart disease, high blood pressure, bone disease, or anemia.Causes of chronic kidney disease include diabetes, high blood pressure, glomerulonephritis, and polycystic kidney disease. Risk factors include a family history of the condition. Diagnosis is generally by blood tests to measure the glomerular filtration rate and urine tests to measure albumin. Further tests such as an ultrasound or kidney biopsy may be done to determine the underlying cause. A number of different classification systems exist.Screening at-risk people is recommended. Initial treatments may include medications to manage blood pressure, blood sugar, and lower cholesterol. NSAIDs should be avoided. Other recommended measures include staying active and certain dietary changes. Severe disease may require hemodialysis, peritoneal dialysis, or a kidney transplant. Treatments for anemia and bone disease may also be required.Chronic kidney disease affected 753 million people globally in 2016, including 417 million females and 336 million males. In 2015 it resulted in 1.2 million deaths, up from 409,000 in 1990. The causes that contribute to the greatest number of deaths are high blood pressure at 550,000, followed by diabetes at 418,000, and glomerulonephritis at 238,000.

More about Chronic Kidney Disease
Browse All Tags